*3.6. Sensitivity Analysis*

Findings of the direct pairwise meta-analysis and the relative effect estimates for ORR and PFS using the frequentist approach are presented in Tables S3–S5. The findings were similar to those by using the Bayesian approach (Tables 1 and 2).


**Table1.**Comparativeefficacyoftargetedtherapiesforoverallresponserateinthenetworkmeta-analysisbasedontheBayesianapproach. Drugstreatment.comparison is shown twice in the table, once with drug A vs. drug B and once with drug B vs. drug A. Significant results are in italic and underscored. RR, response ratio; CI, confidenceinterval; ORR: overall response rate; Afat, afatinib; Alec, alectinib; Beva, bevacizumab; Cabo, cabozantinib; Ceri, ceritinib; Cetu, cetuximab; Chem, chemotherapy; Criz, crizotinib; Dum,dummy; Erlo, erlotinib; Gefi, gefitinib; Osim, osimertinib; Ramu, ramucirumab; Vand, vandetanib.



table, once with drug A vs. drug B and once with drug B vs. drug A. Significant results are in italic andsurvival. Afat, afatinib; Alec, alectinib;. Beva, bevacizumab; Cabo, cabozantinib; Ceri, ceritinib; Cetu, cetuximab;Gefi,gefitinib;Osim,osimertinib;Ramu,ramucirumab;Vand,vandetanib.

 underscored.

 HR, hazard ratio; CI, confidence interval; PFS:

 Chem,

chemotherapy;.

 Criz, crizotinib; Dum, dummy; Erlo, erlotinib;

progression-free
